BioSpace News Archive

Cell Expansion market is projected to reach US$ 42,837.11 Mn in 2027 from US$ 11,929.43 Mn in 2018. The market is projected to grow with a CAGR of 15.6% from 2019-2027.

The dental milling machine market was valued at US$ 1,485.0 million in 2018 and it is projected to reach US$ 3,203.1 million in 2027; it is expected to grow at a CAGR of 9.2% from 2019 to 2027.

The custom antibody market was valued at US$ 833.71 million by 2028 from US$ 409.26 million in 2021; it is estimated to grow at a CAGR of 10.7% from 2021 to 2028.

The generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.

Kadmon Holdings, Inc. announced that the U.S. Food and Drug Administration has approved REZUROCK™ 200 mg once daily for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close.

Everside Health Group, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that it has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana’s CT-179, a drug therapy for the treatment of glioblastoma (GBM), medulloblastoma (MB), and other brain cancers.

(NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.

Immunofluorescence assay is a method involved in antibody-antigen reactions.